If you are researching prescription medications for weight management, you have probably seen tirzepatide and Wegovy compared online.
The comparison can be confusing because the names do not refer to the same type of thing.
Wegovy is a brand name for semaglutide. Tirzepatide is an active ingredient used in prescription medications including Zepbound and Mounjaro.
For weight management, the most relevant comparison is usually Wegovy vs Zepbound, because Zepbound contains tirzepatide and is FDA-approved for chronic weight management in eligible adults.
The main difference is how the medications work:
- Wegovy contains semaglutide and acts at the GLP-1 receptor.
- Tirzepatide acts at both GIP and GLP-1 receptors.
- Zepbound is the tirzepatide brand used for chronic weight management.
- Both are prescription medications with their own FDA-approved uses, warnings, contraindications, side effects, and eligibility criteria.
Neither medication is automatically the right option for every person.
Your medical history, current medications, cardiovascular health, diabetes status, sleep apnea, pregnancy plans, side-effect risk, insurance coverage, treatment goals, and response to previous treatment can all affect the decision.
Important medical information: This article is for education only. Do not start, stop, combine, switch, or change the dose of a prescription medication based on an online comparison. Treatment decisions should be made with a qualified healthcare professional using your individual medical history and the current prescribing information.
Tirzepatide vs Wegovy: Quick Comparison
| Wegovy | Tirzepatide / Zepbound |
|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Weight-management brand | Wegovy | Zepbound |
| Main receptor activity | GLP-1 | GIP + GLP-1 |
| Prescription required | Yes | Yes |
| Chronic weight management | FDA-approved for eligible patients | FDA-approved as Zepbound for eligible adults |
| Cardiovascular-risk reduction | Yes, for a specific adult population | Different labeled indications |
| Obstructive sleep apnea | No specific OSA indication | Zepbound is approved for certain adults with obesity and moderate-to-severe OSA |
| Common side effects | Primarily gastrointestinal | Primarily gastrointestinal |
| Should you choose based only on average weight loss? | No | No |
The important point is that these medications are not interchangeable simply because they are both discussed as GLP-1 weight-management treatments.
Wegovy, Semaglutide, Tirzepatide, Zepbound and Mounjaro Explained
Understanding the names makes the comparison much easier.
Wegovy
Wegovy is a brand name for semaglutide.
Semaglutide acts at the GLP-1 receptor and is used in several branded prescription medications with different FDA-approved indications.
Wegovy is the semaglutide brand used for chronic weight management in eligible patients.
Semaglutide
Semaglutide is the active ingredient in Wegovy.
Other medications may also contain semaglutide, but that does not mean they have the same indication, dosing, formulation, or FDA-approved label as Wegovy.
Drip Lounge also provides more information about semaglutide and weight management.
Tirzepatide
Tirzepatide is an active ingredient that acts at both GIP and GLP-1 receptors.
It is used in more than one FDA-approved branded medication.
Zepbound
Zepbound contains tirzepatide and is approved for chronic weight management in eligible adults.
It also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
Mounjaro
Mounjaro also contains tirzepatide, but its FDA-approved uses are different from Zepbound.
That distinction matters.
The active ingredient alone does not tell you the full approved use of a medication. The brand, indication, formulation, patient population, and current prescribing information all matter.
Learn more about tirzepatide.
How Do Wegovy and Tirzepatide Work?
Both medications affect hormone pathways involved in appetite, food intake, digestion, and glucose-related signaling, but they do not work in exactly the same way.
Wegovy: GLP-1 Receptor Activity
Wegovy contains semaglutide, a GLP-1 receptor agonist.
GLP-1 is involved in several processes related to:
- Appetite
- Food intake
- Glucose-dependent insulin secretion
- Gastric emptying
- Blood-sugar regulation
Effects on appetite and food intake contribute to semaglutide's role in chronic weight management.
Tirzepatide: GIP + GLP-1 Receptor Activity
Tirzepatide acts at two receptors:
GIP + GLP-1
Both hormones participate in nutrient-responsive metabolic signaling.
This dual-receptor activity makes tirzepatide pharmacologically different from semaglutide.
However, an additional receptor target does not automatically mean that tirzepatide is the right medication for every person.
Mechanism is not a personalized treatment recommendation.
What Does the Research Show?
Both Wegovy and Zepbound have large clinical-trial programs supporting their approved uses.
More recently, researchers have also compared tirzepatide and semaglutide directly.
Head-to-Head Research
The SURMOUNT-5 trial directly compared tirzepatide and semaglutide in adults with obesity who did not have type 2 diabetes.
After 72 weeks, average weight reduction was greater in the tirzepatide group than in the semaglutide group.
Average change from baseline body weight was approximately:
- Tirzepatide: −20.2%
- Semaglutide: −13.7%
Average waist-circumference reduction was also greater with tirzepatide.
These results are useful because they come from a direct comparison rather than from two separate studies.
But they should still be interpreted carefully.
A clinical-trial average does not tell you exactly how one person will respond.
Trial participants had specific:
- Eligibility criteria
- Treatment protocols
- Follow-up
- Lifestyle support
- Monitoring
- Medication exposure
Some people lose more weight than the trial average. Others lose less. Some discontinue treatment because of side effects or other reasons.
So the results should not be used as a promise of a specific amount of weight loss.
Is Tirzepatide Better Than Wegovy?
There is no single answer that applies to everyone.
If the question is specifically:
Which medication produced greater average weight reduction in the SURMOUNT-5 trial?
Tirzepatide produced greater average weight reduction than semaglutide in that study population.
But treatment decisions involve much more than one weight-loss percentage.
For example:
- Someone with established cardiovascular disease may need to consider Wegovy's cardiovascular-risk-reduction indication.
- Someone with obesity and moderate-to-severe obstructive sleep apnea may need to consider Zepbound's OSA indication.
- Someone else may tolerate one medication better than the other.
- Insurance may cover one and not the other.
- Medical history may also make one option inappropriate.
Instead of asking only:
“Which one is better?”
a more useful question is:
“Which medication, if either, is appropriate for my health history, treatment goals, risks, and approved indication?”
FDA-Approved Uses: Where Wegovy and Zepbound Differ
Both medications have approved weight-management uses, but their labels are not identical.
Wegovy
Wegovy is approved for chronic weight management in eligible adults and certain adolescents.
It also has an FDA-approved cardiovascular indication for certain adults with established cardiovascular disease and overweight or obesity.
Zepbound
Zepbound is approved for chronic weight management in eligible adults.
It also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.
This is one reason medication choice should not be reduced to a simple comparison of weight-loss percentages.
Is Wegovy Approved for Cardiovascular Risk Reduction?
Yes, for a specific population.
Wegovy is FDA-approved to reduce the risk of major cardiovascular events in adults with:
established cardiovascular disease + obesity or overweight.
Major cardiovascular events include:
- Cardiovascular death
- Nonfatal heart attack
- Nonfatal stroke
This does not mean Wegovy is automatically appropriate for everyone who has cardiovascular risk factors.
The specific indication and the patient's medical history still matter.
Is Zepbound Approved for Sleep Apnea?
Yes.
Zepbound is FDA-approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, together with appropriate lifestyle measures.
Obstructive sleep apnea should still be properly evaluated and monitored.
Medication also does not automatically replace treatments such as positive airway pressure when those treatments are clinically indicated.
Tirzepatide vs Wegovy Side Effects
Both Wegovy and tirzepatide-based medications can cause side effects.
The most commonly reported effects are gastrointestinal.
They can include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal discomfort or pain
- Indigestion
- Changes in appetite
Other safety considerations may include:
- Gallbladder problems
- Pancreatitis
- Dehydration
- Kidney complications related to fluid loss
- Low blood sugar when combined with certain diabetes medications
- Delayed gastric emptying
- Severe allergic reactions
- Thyroid-related warnings
Individual tolerability varies.
Some people may tolerate one medication better than another.
That means it is not accurate to simply say that Wegovy or tirzepatide “has more side effects” for everyone.
Which Has More Side Effects?
There is no universal answer.
Both medications commonly cause gastrointestinal side effects.
In the direct SURMOUNT-5 comparison, gastrointestinal adverse events were common with both treatments and were generally mild to moderate.
However, averages from clinical trials do not predict exactly what one patient will experience.
Side-effect risk should be considered alongside:
- Medical history
- Current medications
- Treatment goals
- Previous medication response
- Hydration status
- Gastrointestinal conditions
- Diabetes treatment
Important Safety Considerations
Both Wegovy and Zepbound include important safety information.
Tell your healthcare professional if you have a personal or family history of:
- Medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
You should also discuss:
- Pregnancy
- Plans for pregnancy
- Breastfeeding
- Diabetes
- Insulin or sulfonylurea use
- Previous pancreatitis
- Gallbladder disease
- Kidney disease
- Dehydration risk
- Significant gastrointestinal disease
- Severe gastroparesis
- Previous severe allergic reactions
- Planned surgery or anesthesia
- Other weight-management medications
- Compounded semaglutide or tirzepatide products
This is not a complete screening list.
Your clinician should review the official prescribing information and your individual medical history before treatment.
Can I Take Wegovy and Tirzepatide Together?
Wegovy and tirzepatide should not be combined as a self-directed weight-management strategy.
Wegovy contains a GLP-1 receptor agonist, while tirzepatide also acts at the GLP-1 receptor in addition to GIP.
Taking medications with overlapping actions does not simply create “more weight loss.”
It may increase treatment complexity and potential adverse effects.
Do not combine Wegovy, Zepbound, Mounjaro, or other medications in these classes unless specifically directed by a qualified clinician.
Can I Switch From Wegovy to Tirzepatide?
A clinician may consider switching someone from Wegovy to a tirzepatide-based medication in some situations.
Reasons might include:
- Treatment response
- Side effects
- Change in health goals
- Insurance coverage
- Availability
- Another medical consideration
However, there is no universal online switching schedule that is appropriate for everyone.
A clinician may need to review:
- Your current medication
- Current treatment plan
- Previous response
- Side effects
- Gastrointestinal symptoms
- Diabetes status
- Other medications
- Medical history
- Reason for switching
Do not use an online dose-conversion chart or attempt to create your own switching schedule.
Who May Need Additional Caution?
A healthcare professional should review whether either medication is appropriate based on your current health and medical history.
Make sure your clinician knows if you have or have had:
- Medullary thyroid carcinoma
- MEN2
- Type 1 diabetes
- Type 2 diabetes
- Pancreatitis
- Gallbladder disease
- Kidney disease
- Significant gastrointestinal disease
- Severe gastroparesis
- Severe allergic reactions
- Pregnancy or breastfeeding
- An eating disorder
- Upcoming surgery or anesthesia
- Other prescription weight-management medications
- Compounded medications
Medication decisions should be individualized.
Tirzepatide vs Wegovy: What Should You Consider?
Rather than focusing only on which medication produced greater average weight loss, consider the broader clinical picture.
| Decision Factor | Why It Matters |
|---|
| Approved indication | Each medication has specific FDA-approved uses |
| Medical history | Certain conditions may affect safety or eligibility |
| Current medications | Interactions and low-blood-sugar risk may matter |
| Cardiovascular disease | Wegovy has a cardiovascular-risk-reduction indication for a defined population |
| Sleep apnea | Zepbound has an OSA indication for certain adults with obesity |
| Diabetes | Diabetes status can affect treatment and monitoring |
| Side-effect tolerance | Gastrointestinal and other effects can affect long-term treatment |
| Pregnancy plans | Important for treatment planning |
| Insurance coverage | Coverage varies significantly |
| Out-of-pocket cost | Long-term affordability matters |
| Follow-up care | These treatments require appropriate clinical monitoring |
| Nutrition | Important during weight loss |
| Muscle health | Weight loss should not be evaluated only by scale weight |
| Personal goals | Health outcomes extend beyond a number on the scale |
Are Compounded Products the Same as Wegovy or Zepbound?
No.
Compounded semaglutide and compounded tirzepatide are not the same as FDA-approved Wegovy or Zepbound.
Compounded medications do not go through the same FDA premarket review process for safety, effectiveness, and quality as FDA-approved branded medications.
Compounding may sometimes have a legitimate clinical role, but it is a separate pathway with different quality, regulatory, pharmacy, and sourcing considerations.
Do not assume that something marketed online as:
- “Semaglutide”
- “Tirzepatide”
- “GLP-1”
- “Generic Wegovy”
- “Generic Zepbound”
- “Research peptide”
is equivalent to an FDA-approved branded medication.
Before receiving any product, ask:
- What exactly is the active ingredient?
- Is this the FDA-approved branded medication or a compounded product?
- Who is prescribing it?
- Which pharmacy is dispensing it?
- Is the pharmacy appropriately licensed?
- Why is a compounded product being considered?
- What quality controls apply?
- What follow-up is included?
- What should happen if you experience an adverse reaction?
Avoid products sold as “research use only” for self-administration.
What Should I Discuss With a Clinician Before Starting?
Before starting a prescription weight-management medication, be prepared to discuss more than your current weight.
Bring information about:
- Your main health goals
- Weight history
- Previous weight-management attempts
- Current prescription medications
- Supplements
- Over-the-counter products
- Diabetes or prediabetes
- Cardiovascular disease
- Sleep apnea
- Pancreatitis
- Gallbladder disease
- Kidney disease
- Gastrointestinal problems
- Pregnancy or plans for pregnancy
- Breastfeeding
- Thyroid cancer or MEN2 history
- Previous side effects from weight-management medications
- Upcoming surgery, anesthesia, or medical procedures
- Insurance coverage
- Out-of-pocket budget
You should also ask:
- How will progress be measured?
- What side effects should prompt a call?
- Which symptoms require urgent care?
- What nutrition and protein intake should I maintain?
- How will muscle health be monitored?
- What happens if I cannot tolerate the medication?
- What happens if insurance stops covering it?
- What follow-up care is included?
Compare Weight-Management Options With a Clinician
Online comparisons can help you understand the differences between medications.
They cannot determine which treatment is appropriate for your individual health.
A clinician-guided evaluation can consider your:
- Medical history
- Current medications
- Treatment goals
- Cardiovascular health
- Metabolic health
- Side-effect risk
- Previous treatment response
- Insurance and access
Book a Virtual Consultation →
You can also explore Drip Lounge's Weight Loss & Metabolism options.
Frequently Asked Questions
Is tirzepatide the same as Wegovy?
No.
Wegovy contains semaglutide. Tirzepatide is a different active ingredient used in medications including Zepbound and Mounjaro.
Wegovy acts at the GLP-1 receptor, while tirzepatide acts at both GIP and GLP-1 receptors.
Is tirzepatide better than Wegovy?
Neither medication is automatically better for everyone.
In a direct clinical trial involving adults with obesity without type 2 diabetes, tirzepatide produced greater average weight reduction than semaglutide.
However, treatment choice also depends on approved indication, medical history, cardiovascular disease, sleep apnea, diabetes, side effects, pregnancy plans, cost, access, and clinician assessment.
Can I take Wegovy and tirzepatide together?
Do not combine Wegovy and tirzepatide as a self-directed treatment.
They have overlapping GLP-1-related effects, and using them together is not a standard weight-management strategy.
A qualified clinician should manage any changes in prescription treatment.
Can I switch from Wegovy to tirzepatide?
Switching may be considered in some situations, but it should be planned by a clinician.
Your current medication, treatment response, side effects, medical history, other medications, and reason for switching should all be reviewed.
Do not use an online conversion chart to switch medications yourself.
Which has more side effects?
Both medications commonly cause gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and abdominal symptoms.
Individual tolerability varies, so one medication cannot be described as universally having more side effects for every person.
Is Wegovy approved for cardiovascular risk reduction?
Yes.
Wegovy is FDA-approved to reduce the risk of major cardiovascular events in certain adults with established cardiovascular disease and either obesity or overweight.
That indication does not apply automatically to every person with cardiovascular risk.
Is Zepbound approved for sleep apnea?
Yes.
Zepbound is FDA-approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Eligibility and treatment planning should be reviewed by a qualified clinician.
Are compounded products the same as Wegovy or Zepbound?
No.
Compounded semaglutide or tirzepatide products are not FDA-approved Wegovy or Zepbound.
They may have different sourcing, formulation, regulatory, quality-control, and pharmacy considerations.
What should I discuss with a clinician before starting?
Discuss your medical history, current medications, diabetes status, cardiovascular health, sleep apnea, gastrointestinal conditions, pancreatitis or gallbladder history, kidney health, pregnancy plans, thyroid cancer or MEN2 history, previous treatments, side-effect concerns, insurance coverage, and follow-up plan.
Your clinician can also help determine how nutrition, physical activity, muscle health, and other factors should be supported during treatment.
Related Reading
Medical Disclaimer
This article is for educational purposes only and is not a substitute for individualized medical advice, diagnosis, or treatment.
Do not start, stop, combine, switch, or change the dose of a prescription medication without guidance from a qualified healthcare professional.
Prescription eligibility, FDA-approved indications, contraindications, warnings, insurance coverage, and treatment recommendations can change. The current prescribing information and your individual health history should be reviewed before treatment.
